The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Open accessAbstract
Next-Generation Gene Therapy: Few disciplines in contemporary clinical research have experienced the high expectations directed at the gene therapy field. However, gene therapy has been challenging to translate to the clinic, often because the therapeutic gene is expressed at insufficient levels in the patient or because the gene delivery vector integrates near protooncogenes, which can cause leukemia (see the Perspective by Verma ). Biffi et al. ( 1233158 , published online 11 July) and Aiuti et al. ( 1233151 ; published online 11 July) report progress on both fronts in gene therapy trials of three patients with metachromatic leukodystrophy (MLD), a neurodegenerative disorder, and three patients with Wiskott-Aldrich syndrome (WAS), an immunodeficiency disorder. Optimized lentiviral vectors were used to introduce functional MLD or WAS genes into the patients' hematopoietic stem cells (HSCs) ex vivo, and the transduced cells were then infused back into the patients, who were then monitored for up to 2 years. In both trials, the patients showed stable engraftment of the transduced HSC and high expression levels of functional MLD or WAS genes. Encouragingly, there was no evidence of lentiviral vector integration near proto-oncogenes, and the gene therapy treatment halted disease progression in most patients. A longer follow-up period will be needed to further validate efficacy and safety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [68]
In the citing paper
“However, the clonal integration site expansions do not appear to be related to oncogenic selection [54].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [54]
In the citing paper
“In the CF clinical field recent pre-clinical studies provided encouraging results on lentiviral-mediated CFTR delivery which are leading to the preparation of a first-in-man lentivirus trial in patients with CF11,57.”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [57]
In the citing paper
“Unlike the retroviral vectors used in those studies, the Lenti-D lentiviral vector (as well as other lentiviral and gamma-retro-viral vectors that are enhancer-deleted with the use of a self-inactivating vector design) so far appears to reduce the risk of mutagenesis.29–32”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [31]
Citations
Cites
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175 · cited 1×
“Recent studies in mice have shown that microglia mostly originates from an early seeding of neural tissues by embryonic lineage macrophages followed by in situ turnover under homeostatic conditions (32).”
BackgroundIn Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Self-citationLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Self-citationInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“(HSPCs) has the potential to trigger leukemia through insertionalmutagenesis (14, 18).”
BackgroundHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 3×
“These gene classes were the same, or shared >75% genes, with gene classes overrepresented in the ALD HSC-GT (17, 29) (Fig.”
BackgroundMethodSelf-citationHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Self-citationTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationTHE GROSS MOTOR FUNCTION MEASURE: A MEANS TO EVALUATE THE EFFECTS OF PHYSICAL THERAPY
Russell, D. J., Rosenbaum, P. L., Cadman, D. T., Gowland, C., Hardy, S., & Jarvis, S. (1989) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1989.tb04003.x · Cited by 1,035
Research works printed but not linked: 1
- 10.1002/(SICI)1098-1004(1997)9:3<234::AID-HUMU4>3.0.CO;2-7 · doi:10.1002/(sici)1098-1004(1997)9:3<234::aid-humu4>3.0.co;2-7
Cited by
Microglia Biology: One Century of Evolving Concepts
Prinz, M., Jung, S., & Priller, J. (2019) · Cell · doi:10.1016/j.cell.2019.08.053 · Cited by 1,525
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“leukodystrophy LV ARSA (117, 154) San Raffaele Telethon Institute of”
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Self-citationGene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Metadata
- Authors
- Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., Benedicenti, F., Vallanti, G., Biasco, L., Leo, S., Kabbara, N., Zanetti, G., Rizzo, W. B., Mehta, N. A. L., Cicalese, M. P., Casiraghi, M., Boelens, J. J., Del Carro, U., Dow, D. J., Schmidt, M., Assanelli, A., Neduva, V., Di Serio, C., Stupka, E., Gardner, J., von Kalle, C., Bordignon, C., Ciceri, F., Rovelli, A., Roncarolo, M. G., Aiuti, A., Sessa, M., & Naldini, L.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- Vita-Salute San Raffaele University (IT)
- University of Perugia (IT)
- MolMed (Italy) (IT)
- Center for Advanced Studies Research and Development in Sardinia (IT)
- Rafik Hariri University Hospital (LB)
- University of Nebraska Medical Center (US)
- GlaxoSmithKline (United Kingdom) (GB)
- University Medical Center Utrecht (NL)
- Neurology Unit, Department of Neurology, San Raffaele Scientific Institute, 20132 Milan, Italy.
- German Cancer Research Center (DE)
- Vita-Salute San Raffaele University, 20132 Milan, Italy.
- GlaxoSmithKline (United States) (US)
- Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, 69120 Heidelberg, Germany.
- Azienda Ospedaliera San Gerardo (IT)
- University of Rome Tor Vergata (IT)
- Corresponding author
- Biffi, Alessandra
- Montini, Eugenio
- Naldini, Luigi
- ORCID
- Biffi, Alessandra
- Montini, Eugenio
- Fumagalli, Francesca
- Plati, Tiziana
- Baldoli, Cristina
- Martino, Sabata
- Calabria, Andrea
- Benedicenti, Fabrizio
- Biasco, Luca
- Leo, Simone
- Zanetti, Gianluigi
- Rizzo, William B.
- Cicalese, Maria Pia
- Boelens, Jaap J.
- Schmidt, Manfred
- Neduva, Victor
- Stupka, Elia
- Ciceri, Fabio
- Rovelli, Attilio
- Roncarolo, Maria Grazia
- Aiuti, Alessandro
- Sessa, Maria
- Naldini, Luigi
- Venue
- Science
- Published
- 2013-08-23
- Volume
- 341
- Issue
- 6148
- Pages
- 1233158-1233158
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2089319449
- Cited by
- 1,180
- References
- 62
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 64 · 2023: 62 · 2022: 60 · 2021: 74 · 2020: 92 · 2019: 101 · 2018: 98 · 2017: 109 · 2016: 133 · 2015: 147 · 2014: 133 · 2013: 31
- FWCI
- 97.94
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- metachromatic leukodystrophy, Wiskott-Aldrich syndrome, lentiviral vectors, hematopoietic stem cell gene therapy, ex vivo gene transfer, leukemia risk, HSC engraftment, neurodegenerative diseases, immunodeficiency, disease progression
- MeSH terms
- Brain, Cerebroside-Sulfatase, DNA Damage, Follow-Up Studies, Genetic Engineering, Genetic Vectors, Hematopoietic Stem Cells, Humans, Leukodystrophy, Metachromatic, Magnetic Resonance Imaging, Transduction, Genetic, Genetic Therapy, Lentivirus, Virus Integration, Treatment Outcome, Hematopoietic Stem Cell Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. https://app.cochat.ai/papers/10.1126/science.1233158
- The paper
- Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., Benedicenti, F., Vallanti, G., Biasco, L., Leo, S., Kabbara, N., Zanetti, G., Rizzo, W. B., Mehta, N. A. L., Cicalese, M. P., . . . Naldini, L. (2013). Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. Science. https://doi.org/10.1126/science.1233158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.